Human adipocyte differentiation and composition of disease-relevant lipids are regulated by miR-221-3p.


Journal

Biochimica et biophysica acta. Molecular and cell biology of lipids
ISSN: 1879-2618
Titre abrégé: Biochim Biophys Acta Mol Cell Biol Lipids
Pays: Netherlands
ID NLM: 101731727

Informations de publication

Date de publication:
01 2021
Historique:
received: 05 08 2020
revised: 07 10 2020
accepted: 11 10 2020
pubmed: 20 10 2020
medline: 14 4 2021
entrez: 19 10 2020
Statut: ppublish

Résumé

MicroRNA-221-3p (miR-221-3p) is associated with both metabolic diseases and cancers. However, its role in terminal adipocyte differentiation and lipid metabolism are uncharacterized. miR-221-3p or its inhibitor was transfected into differentiating or mature human adipocytes. Triglyceride (TG) content and adipogenic gene expression were monitored, global lipidome analysis was carried out, and mechanisms underlying the effects of miR-221-3p were investigated. Finally, cross-talk between miR-221-3p expressing adipocytes and MCF-7 breast carcinoma (BC) cells was studied, and miR-221-3p expression in tumor-proximal adipose biopsies from BC patients analyzed. miR-221-3p overexpression inhibited terminal differentiation of adipocytes, as judged from reduced TG storage and gene expression of the adipogenic markers SCD1, GLUT4, FAS, DGAT1/2, AP2, ATGL and AdipoQ, whereas the miR-221-3p inhibitor increased TG storage. Knockdown of the predicted miR-221-3p target, 14-3-3γ, had similar antiadipogenic effects as miR-221-3p overexpression, indicating it as a potential mediator of mir-221-3p function. Importantly, miR-221-3p overexpression inhibited de novo lipogenesis but increased the concentrations of ceramides and sphingomyelins, while reducing diacylglycerols, concomitant with suppression of sphingomyelin phosphodiesterase, ATP citrate lyase, and acid ceramidase. miR-221-3p expression was elevated in tumor proximal adipose tissue from patients with invasive BC. Conditioned medium of miR-221-3p overexpressing adipocytes stimulated the invasion and proliferation of BC cells, while medium of the BC cells enhanced miR-221-3p expression in adipocytes. Elevated miR-221-3p impairs adipocyte lipid storage and differentiation, and modifies their ceramide, sphingomyelin, and diacylglycerol content. These alterations are relevant for metabolic diseases but may also affect cancer progression.

Identifiants

pubmed: 33075494
pii: S1388-1981(20)30233-X
doi: 10.1016/j.bbalip.2020.158841
pii:
doi:

Substances chimiques

14-3-3 Proteins 0
ADIPOQ protein, human 0
Adiponectin 0
Ceramides 0
FABP4 protein, human 0
FAS protein, human 0
Fatty Acid-Binding Proteins 0
MIRN221 microRNA, human 0
MicroRNAs 0
Sphingolipids 0
Triglycerides 0
YWHAG protein, human 0
fas Receptor 0
SCD1 protein, human EC 1.14.19.1
Stearoyl-CoA Desaturase EC 1.14.19.1
DGAT1 protein, human EC 2.3.1.20
DGAT2 protein, human EC 2.3.1.20
Diacylglycerol O-Acyltransferase EC 2.3.1.20
Lipase EC 3.1.1.3
PNPLA2 protein, human EC 3.1.1.3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

158841

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Maria A Ahonen (MA)

Minerva Foundation Institute for Medical Research, Biomedicum 2U, Helsinki, Finland.

Muhammad Yasir Asghar (MY)

Minerva Foundation Institute for Medical Research, Biomedicum 2U, Helsinki, Finland.

Suvi J Parviainen (SJ)

Minerva Foundation Institute for Medical Research, Biomedicum 2U, Helsinki, Finland.

Gerhard Liebisch (G)

Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Germany.

Marcus Höring (M)

Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Germany.

Marjut Leidenius (M)

Breast Surgery Unit, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.

Pamela Fischer-Posovszky (P)

Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Germany.

Martin Wabitsch (M)

Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Germany.

Tomi S Mikkola (TS)

University of Helsinki and Helsinki University Hospital, Obstetrics and Gynecology, Helsinki, Finland; Folkhälsan Research Center, Biomedicum, Helsinki, Finland.

Kid Törnquist (K)

Minerva Foundation Institute for Medical Research, Biomedicum 2U, Helsinki, Finland; Cell Biology, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland.

Hanna Savolainen-Peltonen (H)

University of Helsinki and Helsinki University Hospital, Obstetrics and Gynecology, Helsinki, Finland; Folkhälsan Research Center, Biomedicum, Helsinki, Finland.

P A Nidhina Haridas (PAN)

Minerva Foundation Institute for Medical Research, Biomedicum 2U, Helsinki, Finland. Electronic address: nidhina.haridas@helsinki.fi.

Vesa M Olkkonen (VM)

Minerva Foundation Institute for Medical Research, Biomedicum 2U, Helsinki, Finland; Department of Anatomy, Faculty of Medicine, University of Helsinki, Finland. Electronic address: vesa.olkkonen@helsinki.fi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH